Overview

Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath, and blood vessel function. Oxygen will be provided for a period of 8 weeks. Additionally, the investigators plan to investigate if it is helpful to deliver individualized support when providing oxygen therapy, through check-in phone calls with a respiratory therapist and by providing additional educational material.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alberta
Collaborator:
Alberta Boehringer Ingelheim Collaboration